<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003816</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066968</org_study_id>
    <secondary_id>RP 98-15</secondary_id>
    <nct_id>NCT00003816</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer</brief_title>
  <official_title>Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy drugs and total-body irradiation before a donor stem cell
      helps stop the growth of cancer or abnormal cells. It may also stop the patient's immune
      system from rejecting the donor's stem cells. When the healthy stem cells from a donor are
      infused into the patient they may help the patient's bone marrow make stem cells, red blood
      cells, white blood cells, and platelets. It is not yet known which combination chemotherapy
      regimen is most effective when given before a donor stem cell transplant in treating aplastic
      anemia or hematologic cancer.

      PURPOSE: This phase II/III trial is studying different combination chemotherapy regimens to
      compare how well they work when given before donor stem cell transplant in treating patients
      with aplastic anemia or hematologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the morbidity, mortality, and overall outcome of patients with severe aplastic
           anemia or hematologic malignancy treated with standard vs novel conditioning regimens
           followed by allogeneic stem cell transplantation.

        -  Examine the influence of donor histocompatibility on outcome by comparing
           matched/related, mismatched/related (with or without T-cell depletion), and
           matched/unrelated transplants with stratification for type of preparative regimen.

        -  Ensure that patients with uncommon diagnoses will be treated in a uniform fashion with
           the best therapy available.

      OUTLINE: Patients are stratified according to risk of relapse (standard-risk: acute leukemia
      in first complete remission, chronic myelogenous leukemia in first chronic phase, lymphoma in
      sensitive first relapse or second remission, primary or untreated myelodysplastic syndromes,
      or untreated severe aplastic anemia vs high-risk: all others).

      Patients are assigned to one of the following conditioning regimens based on diagnosis, risk
      of relapse, and donor relatedness:

        -  Regimen 1: Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and
           cyclophosphamide IV over 2 hours on days -3 and -2.

        -  Regimen 2: Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and
           anti-thymocyte globulin IV over 4-8 hours on days -5 to -3.

        -  Regimen 3: Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and
           total-body irradiation (TBI) twice daily on days -3 to -1.

        -  Regimen 4: Patients receive fludarabine IV over 30 minutes on days -6 to -2 and
           melphalan IV over 1 hour on days -3 and -2.

        -  Regimen 5: Patients receive etoposide IV over 26 hours beginning on day -5,
           cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1.

        -  Regimen 6: Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24
           hours, and thiotepa IV over 24 hours on days -7 to -4.

        -  Regimen 7: Patients receive fludarabine IV over 30 minutes on days -5 to -1 and
           anti-thymocyte globulin IV over 4-8 hours on days -5 to -2.

        -  Regimen 8: Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI
           twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3
           to -1.

        -  Regimen 9: Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte
           globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days
           -3 and -2.

      All patients then receive donor stem cell infusions on day 0. Some patients may undergo
      involved-field radiotherapy 4-8 weeks after transplant.

      Patients are followed periodically post-transplant.

      PROJECTED ACCRUAL: At least 405 patients will be accrued for this study within 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 19, 1998</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Activity of allogeneic stem cell transplant</measure>
    <time_frame>day 100</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence of donor histocompatibility on outcome</measure>
    <time_frame>Day 100</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">362</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <condition>Nonmalignant Neoplasm</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and total-body irradiation (TBI) twice daily on days -3 to -1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 1 hour on days -3 and -2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive etoposide IV over 26 hours beginning on day -5, cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24 hours on days -7 to -4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fludarabine IV over 30 minutes on days -5 to -1 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3 to -1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_label>Regimen 7</arm_group_label>
    <arm_group_label>Regimen 8</arm_group_label>
    <arm_group_label>Regimen 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_label>Regimen 3</arm_group_label>
    <arm_group_label>Regimen 5</arm_group_label>
    <arm_group_label>Regimen 6</arm_group_label>
    <arm_group_label>Regimen 8</arm_group_label>
    <arm_group_label>Regimen 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 4</arm_group_label>
    <arm_group_label>Regimen 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Regimen 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>Given twice daily for 3 days</description>
    <arm_group_label>Regimen 3</arm_group_label>
    <arm_group_label>Regimen 5</arm_group_label>
    <arm_group_label>Regimen 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of one of the following:

               -  Severe aplastic anemia as defined by either of the following:

                    -  Marrow cellularity (&lt; 25% [or 25-50% cellularity with &lt; 30% of remaining
                       cells hematopoietic in origin])

                    -  At least 2 of the following abnormal peripheral blood counts:

                         -  Reticulocyte count &lt; 1% (corrected for hematocrit)

                         -  Platelet count &lt; 20,000/mm^3

                         -  Neutrophil count &lt; 500/mm^3

               -  Histologically confirmed hematologic malignancy, including any of the following:

                    -  Acute leukemia

                         -  Resistant or recurrent disease after combination chemotherapy with at
                            least one standard regimen OR in first remission and at high risk of
                            relapse

                         -  Acute myeloid leukemia (AML) (antecedent myelodysplastic syndromes
                            [MDS], secondary AML, or high-risk cytogenetic abnormalities)

                         -  Acute lymphoblastic leukemia (ALL) (high-risk cytogenetic
                            abnormalities)

                    -  Chronic myeloid leukemia (CML)

                         -  Chronic phase, accelerated phase, or blast phase

                    -  Myeloproliferative disorders or MDS, including any of the following:

                         -  Myelofibrosis

                         -  Polycythemia vera*

                         -  Essential thrombocythemia*

                         -  Refractory anemia

                         -  Refractory anemia with excess blasts

                         -  Refractory anemia with excess blasts in transformation

                         -  Chronic myelomonocytic leukemia NOTE: * Only if transformed to AML or
                            MDS

                    -  Lymphoproliferative disease

                         -  Recurrent or persistent, symptomatic disease after first-line
                            chemotherapy, including any of the following:

                              -  Chronic lymphocytic leukemia (CLL) (≥ 20% marrow involvement)

                              -  Waldenstrom macroglobulinemia

                              -  Low-grade non-Hodgkin lymphoma

                    -  Intermediate or high-grade non-Hodgkin lymphoma, meeting 1 of the following
                       criteria:

                         -  Resistant or recurrent disease after combination chemotherapy with one
                            standard regimen

                         -  Lymphoblastic lymphoma or small noncleaved cell lymphoma in first
                            remission and at high risk of relapse

                         -  CNS disease

                         -  Bone marrow disease and LDH greater than 300

               -  Solid tumor that would otherwise be treated on RPCI-DS-9115 (or equivalent
                  autologous stem transplant protocol) AND has a syngeneic donor

          -  Autologous bone marrow transplant not possible (or desirable) due to 1 of the
             following:

               -  History of marrow tumor

               -  Inadequate marrow dose

               -  Abnormal marrow histology or function prior to storage

               -  Thrombocytopenia or leukopenia

               -  Marrow cellularity &lt; 20%

          -  Histocompatible donor identified

               -  Well-matched donor, as defined by 1 of the following:

                    -  Family member matched for 5 or 6 HLA specificities (A, B, DR)*

                    -  Unrelated donor meeting compatibility criteria of the National Marrow Donor
                       Program (matched for HLA A, B, and DRB1 antigens)*

                    -  Identical twin sibling

               -  If a compatible cord blood donor is identified and there is no suitable unrelated
                  donor available, patient may receive cord blood transplant NOTE: *Patients ≤ 25
                  years of age may be singly mismatched at the A or B loci

        NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ.
        The terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former terminology
        of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the former
        terminology.

        PATIENT CHARACTERISTICS:

        Age:

          -  4 to 70

        Performance status:

          -  Zubrod 0-2 OR

          -  Karnofsky 70-100%

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  See Disease Characteristics

        Hepatic:

          -  Bilirubin &lt; 3 times normal (unless due to disease)

          -  Alkaline phosphatase &lt; 3 times normal (unless due to disease)

          -  SGOT &lt; 3 times normal (unless due to disease)

          -  Hepatitis B surface antigen negative

          -  No severe hepatic disease that would preclude study participation

        Renal:

          -  Creatinine normal

          -  Creatinine clearance ≥ 50 mL/min

          -  No severe renal disease that would preclude study participation

        Cardiovascular:

          -  Cardiac ventricular ejection fraction ≥ 50% by MUGA or echocardiogram

          -  No uncontrolled or severe cardiovascular disease (e.g., myocardial infarction,
             congestive heart failure, symptomatic angina, life threatening arrhythmia, or
             hypertension within the past 6 months)

        Pulmonary:

          -  DLCO or DLVA ≥ 50% predicted (corrected for hemoglobin or alveolar ventilation)

        Other:

          -  No serious concurrent medical or psychiatric illness

          -  No other serious organ dysfunction (unless due to underlying disease), including the
             following:

               -  Uncontrolled bacterial, viral, or fungal infection

               -  Uncontrolled peptic ulcer disease

               -  Uncontrolled diabetes mellitus

          -  HIV negative

          -  Cytomegalovirus status known

          -  Not pregnant

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  See Disease Characteristics

          -  Pretransplant cytoreductive chemotherapy allowed for patients with relapsed or
             refractory disease

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not eligible for total-body irradiation if prior radiotherapy exceeded the following
             limits:

               -  Mediastinum: 3,600 cGy

               -  Heart: 3,600 cGy

               -  Whole lungs: 1,200 cGy

               -  Small bowel: 3,600 cGy

               -  Kidneys: 1,200 cGy

               -  Whole liver: 1,600 cGy

               -  Cranial spinal: 3,600 cGy

               -  Brain: 4,000 cGy

               -  Retina: 4,000 cGy

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip L. McCarthy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>Burkitt lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <keyword>aplastic anemia</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

